Clinical trials: Gut
Metastatic Colorectal Cancer
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
This study is designed to evaluate the mechanism(s) of resistance to the anti-epidermal growth factor receptor (EGFR) antibody panitumumab given in combination with irinotecan in metastatic colorectal carcinoma (mCRC) patients…
- Trial name
- NCT00891930
- Testing
- Panitumumab, Ganitumab, Irinotecan
- Volunteers
- 74 people
- Sponsor
- NantBioScience, Inc.
Inflammatory Bowel Diseases
First Time in Human Study of Intravenous Interleukin-18 Antibody
GSK1070806 is a humanised monoclonal antibody that blocks a protein present in the body called Interleukin-18. The main purpose of this study is to test GSK1070806 in healthy and obese male subjects with normal immune systems to…
- Trial name
- A18110040 (NCT01035645)
- Testing
- GSK1070806
- Where
- United Kingdom
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Colorectal Cancer
A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
CO40939 is a Phase Ib, open-label, multicenter, single-arm study designed to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of cibisatamab in combination with atezolizumab administered after pretreatment with…
- Trial name
- NCT03866239
- Testing
- Obinutuzumab, Atezolizumab, Cibisatamab
- Where
- 13 sites in United States, Denmark and 2 more
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
Crohn´s Disease
Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease
This study will run in centers in Germany, Denmark, Austria, Czech Republic, and Switzerland, only. This proof-of-concept study aims to evaluate the efficacy of three doses of oral TSO suspension vs.
- Trial name
- TRUST-2 (NCT01279577)
- Testing
- Low dose TSO, Medium dose TSO, High dose TSO
- Where
- Germany
- Volunteers
- 254 people
- Sponsor
- Dr. Falk Pharma GmbH
Colorectal Cancer
DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have metastatic…
- Trial name
- NCT00024401
- Testing
- DHA-paclitaxel
- Where
- 6 sites in United States
- Sponsor
- Theradex
Ulcerative Colitis
Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis
This study conducted a systematic clinical observation of the clinical efficacy of UCB-MNCs in the treatment of hormone-resistant or hormone-dependent ulcerative colitis, in order to observe its clinical safety and efficacy.
- Trial name
- NCT04882683
- Testing
- Prednisone, Azathioprine, Adalimumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shandong Qilu Stem Cells Engineering Co., Ltd.
Colorectal Cancer
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
The purpose of this study is to determine whether overall survival is prolonged in subjects with metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with cetuximab in combination with irinotecan…
- Trial name
- NCT00063141
- Testing
- cetuximab, Irinotecan
- Where
- 188 sites in United States, Australia and 15 more
- Volunteers
- 1,302 people
- Sponsor
- Eli Lilly and Company
Ulcerative Colitis (UC), Healthy Volunteer
Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients.
PALI-2108 is a new oral medication designed to treat ulcerative colitis (UC) by targeting the intestines. It works as a phosphodiesterase-4 (PDE4) inhibitor prodrug, meaning it becomes active only after being processed by…
- Trial name
- NCT06663605
- Testing
- PALI-2108
- Where
- Canada
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Palisade Bio
Colorectal Cancer
Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers
Phase 2A study, assessing the antitumor activity and the safety profile of GM102, a new compound (monoclonal antibody), administered alone or in combination with chemotherapy in patients with locally advanced or metastatic…
- Trial name
- NCT03799731
- Testing
- GM102, Trifluridine/Tipiracil, GM102 expansion
- Where
- 5 sites in Belgium, Czechia
- Volunteers
- 65 people
- Sponsor
- GamaMabs Pharma
COVID-19
Observational Study on the Diagnostic Evaluation of the Intestinal Microbiota of Patients With COVID-19.
In the context of the COVID-19 pandemic, the role of the gut microbiome is yet unknown. The aim of this trial is to evaluate the clinical contribution of the gut microbiome composition and diversity on the disease severity and to…
- Trial name
- EDIFICE (NCT05107245)
- Testing
- 1test1
- Where
- 4 sites in France
- Volunteers
- 143 people
- Sponsor
- Luxia Scientific
Microbial Colonization
Investigating the Impact of Humiome B2 (Colon Delivered Riboflavin) and Riboflavin-overproducer Probiotic Strain Limosilactobacillus Reuteri AMBV339 on Intestinal and Vaginal Microbiome and Health of Healthy Adult Women (The VIAB2L Project)
The goal of this clinical trial is to learn if the probiotic strain Limosilactobacillus reuteri AMBV339 or colon-delivered riboflavin or their combination can change the gut and vaginal microbiome and metabolomics.
- Trial name
- VIAB2L (NCT06425081)
- Testing
- Limosilactobacillus reuteri AMBV339, Humiome B2, Limosilactobacillus reuteri AMBV339 + Humiome B2
- Where
- Belgium
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- dsm-firmenich Switzerland AG
Gastrointestinal Disease, Inflammatory Bowel Disease (IBD)
Elemental 028 Extra Case Studies
Elemental 028 Extra is a nutritionally complete ACBS approved amino acid-based (elemental) feed designed to provide adequate daily amounts of both macronutrients and micronutrients when used as a sole source of nutrition and to…
- Conditions
- Gastrointestinal Disease, Inflammatory Bowel Disease (IBD), Short Bowel, Malabsorption
- Trial name
- E028E (NCT06877923)
- Testing
- Elemental 028 Extra
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Nutricia UK Ltd
Sepsis, Multiple Organ Dysfunction Syndrome
Bovine Intestinal Alkaline Phosphatase for the Treatment of Patients With Sepsis
Eligible patients will receive either AP or matching placebo in a double blind, randomized design and following a 2:1 ratio. All medication will be given in addition to standard care for sepsis patients.
- Trial name
- NCT00430859
- Testing
- Alkaline Phosphatase
- Where
- 10 sites in Belgium, Netherlands
- Volunteers
- 37 people
- Sponsor
- AM-Pharma
Metastatic Colorectal Cancer
Fruquintinib DDI Study With P-gp and BCRP Substrates
Fruquintinib DDI Study with P-gp and BCRP Substrates
- Trial name
- NCT05368805
- Testing
- Fruquintinib, Dabigatran Etexilate, Rosuvastatin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Ulcerative Colitis, Ulcerative Colitis Acute
Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)
The purpose of this study is to compare PL8177 (a melanocortin receptor agonist) to placebo (in a 3:1 ratio-meaning that for every 3 people that get the active drug, one will receive placebo).
- Conditions
- Ulcerative Colitis, Ulcerative Colitis Acute, Ulcerative, Ulcerative Colitis Flare
- Trial name
- PL8177-205 (NCT05466890)
- Testing
- PL8177
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Palatin Technologies, Inc
Colitis, Ulcerative, Crohn's Disease
Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease
The purpose of this study is to assess the concentration of vedolizumab in breast milk of lactating women with active ulcerative colitis (UC) or Crohn's disease (CD) who are receiving vedolizumab therapeutically.
- Trial name
- NCT02559713
- Testing
- Vedolizumab
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- Takeda
Irritable Bowel Syndrome
Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation
Patients suffering from Irritable Bowel Syndrome with predominant constipation will be provided with the study medication. The study medication will be evaluated for its efficacy in relieving the symptoms
- Trial name
- NCT01027260
- Testing
- Itopride HCI 50 mg, Itopride HCI 100 mg
- Where
- 4 sites in Pakistan
- Volunteers
- 268 people
- Sponsor
- Abbott
Colorectal Neoplasms, Melanoma
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.
- Conditions
- Colorectal Neoplasms, Melanoma, Prostatic Neoplasms, Renal Cell Carcinoma
- Trial name
- NCT00378482
- Testing
- CP-675,206 (Tremelimumab)
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Parkinson Disease, Genetic Predisposition
Study of the Genome, Gut Metagenome and Diet of Patients With Incident Parkinson's Disease
A case-control study to identify microbiome and genetic differences between healthy subjects and patients with incident Parkinson's disease.
- Trial name
- NCT04119596
- Testing
- 16S rRNA gene sequencing, DNA-microarray genotyping
- Where
- Russia
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Atlas Biomed
Appendicitis Acute, Appendicitis
Clinical Trial for a Outpatient Clinical Management of Urgent Laparoscopic Appendectomy
The aim of this study is to evaluate the safety and efficacy of outpatient management of uncomplicated acute appendicitis. For this purpose, a randomized clinical trial was designed.
- Trial name
- ASI (NCT05401188)
- Testing
- Outpatient, hospitalization
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- HJ23
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.